Efficacy observation of IAG regimen for acute myelogenous leukemia

Abstract

Objective To assess the therapeutic effect and side effects of IAG priming regimen for the treatment of acute myelogenous leukemia (AML).Methods A retrospective study of 25 AML patients receiving one course of IAG regimen treatment was performed.IAG priming regimen comprised low-dose cytarabine (10 mg/m2 subcutaneously every 12 h on days 1-14),idarubicin (5mg intravenously every other day for 7-8 times) and granulocyte colony-stimulating factor (200 mg/m2 subcutaneously daily on days 1-14).Results After one course induction therapy of IAG regimen,an overall response rate of 80 ％ (20/25) and complete remission rate of 60 ％ (15/25) were achieved.Among the initial diagnosed 17 AML patients,9 got CR,4 got PR.Among the 8 relapsed or refractory patients,6 got CR,1 got PR.Among the 7 AML patients transformed from myelodysplastic syndrome,5 got CR,2 got PR.Among the 11 aged patients (≥ 50 years old),8 achieved CR,1 achieved PR.The main side effects consisted of myelosuppression,gastrointestinal tract reaction and mild or moderate liver or renal impairment.No death was recorded.Conclusion IAG priming regimen is an effective and less toxic treatment protocol for AML patients,including those with high-risk features. Key words: Leukemia, myeloid, acute; IAG priming regimen; Idarubicin; Cytarabine; Granulocyte colony-stimulating factor